leisure time -WSS

leisure time

author：leisure time 2025-09-06 03:54:27 - browse：144

glum Benjamin — health insurance coverage from STAT — Adobe

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Health officials lay out plans to cope with respiratory virus season

hotspot

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

National associations that represent hospice owe an apology

PBMs are inflating the cost of generic drugs. They must be reined in

What should King Charles tell the public about his cancer?

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Medical mystery: When a cough is not just a cough

focus

leisure time

focus

Walensky prepares to leave CDC — and Congress — behind

Study: Spinal cord stimulation helps patients with paralysis walk again

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

People can get long Covid without testing positive for virus: Study

Sports medicine is finally prioritizing gender equality

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Drug repurposing or repositioning? The language matters

What we’ve learned from the Aduhelm mess

How to save PrEP access — and even expand it

A disappointing year of Humira biosimilars

hotspot

Vivek Ramaswamy made waves in the debate, much as in biotech

Republicans love RFK Jr. What's that tell us about health in 2024?

What we’ve learned from the Aduhelm mess

PhRMA lawsuit over Medicare drug price negotiation tossed

A disappointing year of Humira biosimilars

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

explore

hotspot

focus